

**Testimony of Americans for Lower Drug Prices  
Before the Kansas House Committee on Insurance**

**Re: HB 2684**

**March 9, 2026**

Good afternoon, Chairman Sutton, Vice Chairman Bergkamp, Ranking Member Neighbor, and members of the Committee.

Thank you for the opportunity to testify today on behalf of Americans for Lower Drug Prices (ALDP) before your committee in support of House Bill 2684.

My name is Michael Glassner, and I am the co-founder of ALDP, a nonpartisan, nonprofit focused solely on reducing the prices of unaffordable medications for all. I am here today expressing my strong support for the intent of this legislation, capping the price of insulin.

At ALDP, we amplify the patient voice in order to hold drug manufacturers accountable for their high list prices and help ensure access for vulnerable and rural Americans. I am a proud Kansan. I grew up in the small town of Peabody and am a graduate of the University of Kansas. Early in my career, I was fortunate enough to work closely with Senator Bob Dole for over a decade, and during that time I traveled with him to all of our 105 counties and to all 50 states. As you know, Senator Dole was one of the greatest champions of rural America to have ever served in the US Senate. I learned from him the dignity and courage of hardworking rural Americans.

As someone who has had the privilege of serving in senior roles on all three of President Trump's campaigns, I have continued to travel the country, listening to patients and small businesses describe the impossible choices they face because of high drug prices. Time and again on the trail, people would pull us aside and plead with Mr. Trump to do something about rising drug costs, including insulin costs. Those conversations have stayed with me. The problem is real, it is urgent, and it is not going away on its own. To see measures, such as House Bill 2684, advance through the state legislature, makes me especially proud to be a Kansan.

According to the American Diabetes Association, approximately 38 million people in the U.S. have diabetes. In Kansas, around 244,000 adults have been diagnosed with diabetes, representing about 11% of the adult population. In fact, it is consistently in the top ten causes of death in this state. For patients with diabetes, insulin is a must-have, life-sustaining medication, yet in the past decade alone, out-of-pocket costs for insulin have doubled in this country. One in four insulin-dependent patients still ration insulin due to costs. We know that caps can help, but only where they exist.

Capping the price of insulin will provide much-needed relief to those not yet eligible for Medicare and to those most financially burdened today.

As you know, the federal government has taken a step toward addressing the rising price of insulin. The Inflation Reduction Act capped insulin at \$35 per month for Medicare Part D in January of 2023, and for Part B in July of 2023, which has already helped our senior Kansans.

However, the language within House Bill 2684 will help another previously untouched segment of the population: the uninsured, the underinsured, disabled Kansans, and especially those on low and fixed incomes, and working families. The bill represents a meaningful step forward – helping drive down the price of insulin, which is too often out of reach for thousands of Kansans.

Research confirms that caps deliver the greatest relief to the most cost-burdened patients: those in high-deductible plans, those without employer coverage, and those paying full list price. To date, 29 states cap the price of insulin, according to the American Diabetes Association, and I hope Kansas will be the 30th.

We know that the federal government, under President Trump’s leadership, has deeply engaged on the issue of monopoly drug prices. Last month, TrumpRx was launched, providing access to some of the nation’s leading drugs at discounted rates. President Trump also has secured voluntary “Most Favored Nation” agreements with at least 15 pharmaceutical companies to align U.S. drug prices with lower international rates.

We applaud the President for his efforts to tackle skyrocketing drug prices and make health care more affordable for all Americans. But it will take policymakers in Washington and at the state level working together – as laboratories of innovation and as partners – to deliver real, lasting relief to patients like the Kansans in your districts.

Finally, we at ALDP would urge lawmakers in Kansas to go a step further, and consider creating a Prescription Drug Affordability Board, or PDAB, with upper price limit authority. We can look to the 12 other states, such as Colorado, Ohio, New Hampshire, and, just this year, Virginia that have passed PDABs as easily replicable models.

In sum, states cannot wait for Washington to act on rising drug costs. Thank you for the opportunity to address you today regarding this important topic.